

Harish Shrikrishna Bharambe

PhD, ACTREC-TMC

Dr. Harish Shrikrishna Bharambe was a graduate student at ACTREC-TMC in the Neuro-Oncology Lab with Dr. Neelam V. Shirsat. During his PhD tenure, he elucidated functional role of two microRNAs miR-193a and miR-204 in the pathogenesis of medulloblastoma. He demonstrated tumor-suppressive activity of miR-193a in highly aggressive Group 3 medulloblastomas. MiR-193a was found to destabilize the MYC oncoprotein. MiR-193a has therapeutic potential in aggressive cancers having deregulated MYC expression. He also identified miR-204 as a tumor suppressor and a risk-stratification marker in Group 3/Group 4 medulloblastomas. Before joining ACTREC, he did his post-graduation in Pharmaceutical Biotechnology from the National Institute of Pharmaceutical Education and Research, Hajipur. He also worked at the UM-DAE Center for Excellence in Basic Sciences with Dr. Jacinta D'Souza and Prof Deepak Mathur from the Tata Institute of Fundamental Research. He identified a unique mechanism of action of DNA damage induced by intense ultra-short laser pulses. These laser pulses were found to bring about DNA damage by producing low energy electrons, hydroxyl radicals in situ.

